Replay available

Checkit (LSE:CKT) — Results for the six months ended 31 July 2026 (“H1 FY27”)

Results for the six months ended 31 July 2026 (“H1 FY27”) hosted by Checkit (LSE:CKT) on Investor Meet Company. Replay available.

Tue, September 29, 2026 at 9:00 AMendedReplay
Checkit (LSE:CKT) — Results for the six months ended 31 July 2026 (“H1 FY27”)
Company
Checkit PLC (LSE:CKT)
Date
Tue, Sep 29, 2026, 9:00 AM ET
Replay
Watch the replay on this page · 29 min

On 6ix: 6ix.com/event/checkit-plc-ckt-results-for-the-six-months-ended-31-july-2026-h1-fy27

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:01 Good afternoon, and welcome to the CHECKIT PLC investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and could be submitted at any time by the Q and A tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you over to Kit Kite, CEO. Good afternoon, sir. Good afternoon, and thank you everyone for joining us. Today's results mark an important point in CHECKIT's development. We've moved from a period of substantial investment and restructuring into a profitable, more focused business.

0:47 The formal sale process has concluded. It provided extensive external validation of our technology, customer base, and recurring revenue model. And although it did not produce an offer at which the value of the board felt it could recommend, our focus has now moved firmly onto independent execution and demonstrating the greater value that we believe exists within CHECKIT. So today, we will cover the stronger financial foundations established in h one, the simplification of the business, and our two year framework for profitable growth. I'm joined today also, by Chris Shaw, who's our chief financial officer. So I'll cover the business, product strategy, outlook, and Chris will take you through the commercial model and the financial results.

1:36 The central result is our return to adjusted EBITDA profitability. So continuing operations delivered £300,000 of adjusted EBITDA, representing a £1,200,000 improvement on the prior year. We've achieved that alongside revenue growth, a higher recurring revenue mix, and an improved gross margin. So recurring revenue now represents 97% of total revenue, and ARR has increased by 5% to £12,800,000. New bookings increased and churn reduced significantly, giving us positive net commercial momentum. We also generated cash from continuing operating activities, £300,000 this year prior to compared to £2,300,000 outflow last year. To withdraw the legacy product has removed a completely separate legacy technology estate and approximately £700,000 of annualized cost.

2:31 So today, CHECKIT NOW is a profitable, overwhelmingly recurring business able to direct those resources towards one modern platform and a much narrower commercial strategy. So for those of you who are new to the business and for those who've been with us for a while, I'll briefly reexplain what it is that we do or makes us different and unique in this space. So CHECKIT connects the physical world of sensors with the people and the systems responsible for frontline operations. We monitor critical conditions continuously. When something changes, our software then guides the required action and preserves the evidence. We then use the combined sensor and the workflow data to give our customers operational insight.

3:20 This matters most where a failure creates regulatory, financial, or patient safety consequences. There are hardware only providers that can record a condition. There are enterprise quality management systems that can manage documentation, but CHECKIT connects both the live sensor estate, the frontline response, and the compliance records. We sit in between the two, and that's our our our point of differentiation. Once we're embedded in those daily operations, that combination becomes difficult to replace. So we now operate with two clear areas of focus. Medical represents approximately 71% of our continuing revenue, and it's our principal growth engine. Our strongest positions are in the NHS, private hospitals, and US plasma with further opportunity in diagnostics, biotech, and cell and gene therapy.

4:12 These customers value regulatory compliance, reliability, and a complete audit trail. Those requirements also support high switching costs. Retail represents approximately 29% of revenue, and we're concentrating our activity only on what we would call premium multisite customers where sensing, workflow, and regulatory requirements combine to support attractive economics. We're deliberately reducing our attention on fragmented lower value opportunities where acquisition and service costs are too high. So our strategy is to deepen our medical positions and pursue only higher quality retail opportunities. Platform unification is the most important product initiative in this business today. Medical customers currently use a proven monitoring proposition, but they do not yet have the full workflow and analytics capabilities available on our modern platform.

5:06 So next generation medical monitoring brings those capabilities together. Our customers will retain their existing hardware while gaining significantly better software experience. The new platform adds enhanced regulatory functionality, electronic signatures, calibration records, integrated workflows, and a complete alert life cycle. Moving to one cloud platform removes duplicated development and infrastructure. It should allow us to innovate faster, lower our cost to serve, and make a broader range of software available to the installed medical base. The opportunity extends beyond the new interface. It makes our complete monitor, act, and understand proposition available across medical across the entire installed base. Delivery of this is structured into four practical phases.

5:57 By the end of October, we are targeting core regulated monk medical functionality. The end to end CamPlus data flow, CamPlus being our medical product, and a and a completed customer migration design. Then calibration, operational qualification, remaining feature parity are targeted for January. From February onwards, customers will begin running the existing and unified platforms in parallel. Migration will then proceed in controlled phases over several quarters. That timetable reflects our operational capacity and the validation and process changes required by customers. We expect to begin commercial go to market activity in the new calendar year with commercial launch and complete custom migration as separate milestones. As the program progresses, the one code base should improve our development speed, reduce duplicated cost, and create further cross sell opportunities.

6:53 AI is already changing how our engineering organization works. This is so much more than just vibe coding. We've built a structured development framework in which specialist agents, CHECKIT agents, support our software design, development, testing, and documentation. Human human control remains built into the process. Security performance and quality views can block release and define changes require explicit human approval. We're applying this capability directly within the platform unification and interface development program. Early projects indicate the potential for materially faster delivery at substantially lower cost. We will measure our success through delivery speed, product quality, and development cost. This is an internal operating capability that can allow CHECKIT to achieve much more with a focused engineering organization.

7:40 I'll hand over to Chris now to talk about bit more about our economic units and financial performance. Thank you, Keith. A couple of things I would like to highlight about the business and also about the results which we're presenting today. So first of all is the the quality of our revenues. You see here that 97% of our revenue is recurring in nature. Also, the way that we contract with our customers, we so we typically sign a thirty six month contract with our customers. At the end of that thirty six month, it will move on to a twelve month rolling contract. What that means is we have very good visibility of our revenues, of our cash flows, and over our future profitability. I think it's also important to understand how we account for those contracts with our customers.

8:26 So from a revenue perspective, we obviously recognize the revenue over time equally as the contract progresses. From a cost perspective, typically, when we do the installation at the beginning of the contract, we take the full cost of the hardware and the full cost of the installation at the very beginning of the contract. What that means is that the first year of our contracts are typically breakeven and subsequently become increasingly more profitable. And you'll see that feeding through into the gross margin as you see that gross margin gradually increasing over time. The other thing about this business is that what we're saying is very much a mission critical product. We're looking after blood products. We're looking after vaccines. We're ultimately looking after patient safety at the end of the day and also food safety. This means that our customers are not necessarily looking for the cheapest solution, but they're looking for a solution which allows them to comply with the strict regulatory requirements that they're that they're in and also provide an auditable solution as well.

9:25 This again translates into the high gross margin which we're able to deliver from this product as well and also translates into the strong retention rates. You say that we have 94% GRR, but that means that on average, our customers are staying with with us for around about twenty years. Our NRR of 102% is a little bit below where we'd like it to be, so we have said today that we're targeting 105% to 110%. As Keith has highlighted, we have a way to get there, which is through the next generation medical monitoring and through the platform unification, delivering us upsell opportunities to our existing customers. Just looking in terms of the results, you can see that the bookings number has improved in the current period. So we went from a 600,000 of booking in the last period to £700,000 in the current period.

10:13 If you look a little bit deeper into that number, you'll see that we have a greater proportion of bookings from new customers, a greater proportion of bookings from expansion from existing customers and a smaller proportion from price increases. So that is really a strengthening of the quality of those bookings as well. On the other side of the ARR equation, we have reduced the churn from £800,000 to £500,000 So overall, we're making significant improvements on both sides of that ARR equations. We certainly recognize that there's more to do, but we are making progress. On this slide, I think I would really like to highlight the improvement in the adjusted EBITDA. You see that it went from a GBP 900,000 EBITDA loss in the prior period to GBP 300,000 EBITDA profit in the current period. It's a GBP 1,200,000 swing.

11:06 That hasn't that has come from ultimately a change in the cost base of the business. It is a structural change. It is very much embedded into the way that we operate, and it won't be changing back. And therefore, we have significant operational leverage as we move forward. We will continue to be investing in the business, so we will be making investments in the products. As KIT has highlighted, we're finishing the next generation medical monitoring. We're finishing the platform unification. We have investments in go to market. Our objectives, therefore, over the short term is to ensure that we continue to be cash flow breakeven, ensure that we continue to be EBITDA profitable, but not necessarily in the very short term over the next year to drive EBITDA to the highest number possible that will come in the future as those investments deliver results.

11:54 Today, we announced the discontinued operation. That was a product which was provided to a single customer. It added significant complexity to the business, and it held back development of the platform. Ultimately, it had a significant opportunity cost associated with it, and therefore, whilst it did deliver an accounting profit in the period, the overall contribution to the business was negligible. Overall, the business is very much simpler. It is very much lower cost, and growth will convert into EBITDA and cash generation in the future. You see from this slide that our cash flow has been broadly flat over the last twelve months. This contrasts with earlier periods where we were significantly cash consumptive.

12:41 This is obviously a result of the structural change in the cost base. We have sufficient cash to continue moving forward and making the investments which we plan to. We have no external debt on the balance sheet. The only significant liability on our balance sheet is the deferred revenue, which is from customers who pay us annual advance and therefore acts as a working capital funding function for the business. From a capital allocation perspective, our objective, as I said, is very much to preserve cash. We have a focused road map. We'll be funding the platform unification. We'll be funding the go to market, but we'll be disciplined in these investments, and these investments will support future growth. I'll hand you back to Kit. Thank you, Chris. I mean, the key point is that CHECKIT now is a stronger financial foundation from which to invest selectively in growth.

13:32 I'll finish by explaining how we intend to do that. So the board has adopted a two year framework for the next phase of value creation. As Chris mentioned, we intend to sustain adjusted EBITDA profitability and cash generation while building progressively stronger ARR growth. We will pursue that through disciplined investment in the unified platform and medical commercial activity. We've established clear retention objectives. Chris mentioned net revenue retention of up between a 105 and a 110% and gross revenue retention above 95%. Improved retention will help us reduce the amount of new business required simply to replace churn and allows bookings to compound more effectively. The platform unification supports that objective by giving our medical customers more software to adopt while reducing our own cost to serve.

14:20 As as Chris mentioned, delivery will not necessarily be linear, particularly during customer migration, but the direction and measures are clear. We see substantial white space within medical, so I wanna double click on that. However, we will remain selective about where we invest. The immediate opportunities are those closest to our existing customers' references and regulatory capabilities. So the NHS still contains meaningful white space, particularly outside of England, and we have a strong reference base there. So for those that are new, we're present in about a 186 different NHS hospitals and about 86 NHS trusts. For reference, there are almost 2,000 hospitals across The UK for which we have the same use case to be able to deploy time and time again.

15:10 In The US, blood plasma reigns our most established route to growth with related opportunities in blood, tissue, and organ procurement. Again, for those that are new, we have six of the top 10 blood plasma providers in The US on their books already, but there's clearly more to go after. We also see potential in biotech, cell, and gene therapy and diagnostics, including expansion through existing OEM relationships. Selected international markets may offer further opportunity where compliance requirements resemble those we already serve. As always, we will assess each opportunity against conversion evidence, delivery requirements, and capital efficiency. The priority is to increase our share of the available market without spreading resources across too many new areas. Our plan therefore rests on five connected areas of execution.

16:01 First and foremost, we must complete the platform unification. This is the foundation for lower development cost and a better medical pro proposition and more cross sell on the installed base. Secondly, we must deepen our medical positions through the NHS, US plasma, biotech, and existing global accounts. Third, we must keep our retail focused only on larger, higher quality premium customers, and we must exit activity that cannot support attractive economics. Fourth, we must continue to develop The US opportunity through sustained executive attention and targeted periods on the ground. Finally, we must continue to apply AI to measurable productivity gains across product development. The balance matters here. Improve growth without creating an undersplained cost base and protect cash while completing the product investment required for the next phase.

16:58 So in closing, CHECKIT enters this phase as a materially stronger business. We have differentiated technology in markets where monitoring, workflow, and compliance are mission critical. We have 97% recurring revenue, improving retention, and a cost base that have returned this business to profitability. We have a clear product program, a focused commercial strategy, and meaningful operating leverage if we execute successfully. Our priorities are straightforward, protect profitability and cash, complete the unified medical platform, and build progressively stronger recurring revenue growth. We believe that delivering against those priorities can create materially greater value for shareholders. And so with that, I'd like to thank you all, and Chris and I would certainly be pleased to take questions. That's great. Thank you very much for your presentation. If I may just bring back up your cameras. Ladies and gentlemen, please do continue to submit your questions just via the Q and A tab situated on the top right hand corner of your screen. Just while the company take a few moments to review those questions submitted today, I'd like to remind you that recording of this presentation along with a copy of the slides and the published Q and A, can be accessed via investor dashboard.

18:02 As you can see, we have received a number of questions throughout today's presentation. And Chris, could I please ask you to read out the questions and give responses where appropriate to do so, and I'll pick up from you at the end. Thank you. So first question here. In the past, you have said 2027 will be profitable. Do you maintain that outlook? Yes. We've achieved that milestone now. And as we've mentioned throughout this presentation, we expect to continue to improve that over the coming periods. Anything you'd add to that, Chris? No. I think that's right. I think that the results that you've had in the latest periods from the continuing, discontinuing operations and the remainder of the year show that we'll be able to deliver the EBITDA profitability number, which we originally set out to achieve. Next question. Given that 71% of CHECKIT's business is now concentrated in the medical sector, your organic growth relies entirely on NHS trusts. However, individual hospitals heavily mandate purchasing through official framework agreements and approved vendor lists. What is the plan, if any, to circumvent this barrier?

19:05 Well, the short answer is that we're already on all of those frameworks and, preferred supplier list. So we're inside the tent. That's a sort of moat of its own. So that's already achieved. And as I mentioned earlier, it's a pretty proven use case for us now, given the 186 hospitals we're currently in. So we'd expect to continue to expand those over time in the way that we have done. The the hope is that, again, with a unified medical platform and a lower cost to serve, that we can actually be even more competitive on certain NHS tenders where price is one of the leading indicators. So that that that becomes an attractive upside for us. Did you try to move the lost customer on the legacy product to your main technology platform? If so, are you able to see why it wasn't possible?

19:52 Well, short answer is no because it the the the product itself being legacy was focused on a noncore part of this business, and that's what that customer, was particularly interested in. We took the view given that it was negligible in terms of its contribution to the business, and it was a blocker indeed for us completing the platform unification program that the right thing to do with was to retire the the product or sunset the product, alongside the the one customer who's on there. Is the development work needed to complete the unified platform technical difficult technically difficult to do? I'm just thinking about any risks to the achievement of this. It is technically difficult to do, but as you know, we we have a we have a technically competent team. And as I mentioned earlier in the in the in the session, that team is now being augmented, with CHECKIT specific agents that we built up to get the work done. So so far, progress is in line or ahead of management expectations on that on that premise. I don't see a huge amount of risk with that work getting completed in in the timelines we suggested.

21:00 Could you please talk a little about your current position in the NHS and what opportunities you see for growth there? Yes. Similar to the previous. Look. We're we're in we're in 86 different trusts. The use case is predominantly around pharmacy and hematology. That's our kind of that's the that's the primary use case. The NHS is obviously significant in scale, and it's very decentralized. So trusts and individual hospitals tend to make their procurement decisions. You need to be inside all of the procurement frameworks, as I mentioned before, in order to be able to participate. And in almost every instance, the way that they purchase is through some kind of, some form of tender led procurement activity. What we've seen in the past is that we are there's three criteria in which the NHS will award contracts, its technical capability, its quality, its price.

21:51 We almost always score highest on technical capability and quality. And sometimes, we have been we've found out that we are maybe more expensive than a lower lower price comp competitor. So going forwards, we would like to think that we with a lower cost to serve, we can actually compete effectively on price whilst retaining margin, and that then gives us an improved set of conversion metrics to go after. Given the reported 25p level of interest, what prevented the FSP from resulting in a transaction? And do you expect further interest in the business to emerge? So as it relates to the FSP, I mean, worth just briefly commenting on this. We've spent the last six months fielding a significant bidder interest. I'm I'm not at liberty to go into the the exact details because of the takeover panel rules, but, you know, in excess of forty forty to 50 different bidders of expressed interest mixture, as we mentioned in our in our interims update, a mixture of private equity and strategic parties.

22:54 Whilst we got credible executable bids on the table, including one valued at, you know, 25 p that we could see a path to successful closure on, It was ultimately a question around shareholder value, and the board's recommendation or the board's process is that we felt that our business should be able to command better shareholder value than the bids that we currently received, and that's why we've drawn a line in the process as of today. But in terms of go forward business, as as we've mentioned, the management here is focused explicitly on execution and and and remaining independent. That being said, of course, given the process we've just run and given the direction of travel in the business, the board remains open to approaches, and indeed, approaches might well come, but that's for something for down the line.

23:45 There's continuing investment in products, but this has never been reflected in revenue growth. Singer notes suggest limited growth. Why is the business not growing? It's a good question. Well, I don't think the business is not growing. I think that would be an incorrect statement. The business is growing at a rate that is sustainable for its current operation. As I mentioned as we've mentioned in this in this program, one of the holdbacks has been, I would suggest, a split of r and d and indeed go to market, focus around too many legacy platforms. We have cleaned up that estate. And with one unified estate, we expect that this will help us increase the conversion rates that our go to market teams take to the market and, therefore, feed back into more reliable and sustained ARR growth over time.

24:33 And do you have a problem with liaising with different software systems, or you're independent of these? I'm gonna assume that question is some sort of related to the platform and where it sits inside a stack with a with an enterprise buyer. I mean, the short answer is we don't have a problem. We do have different types of customer asking whether they can integrate the CHECKIT platform into a a supply chain management software tool, for example, or a QMS system. And as I mentioned, I think, during the presentation, we actually sit in between those large QMS system providers and then those pure hardware So the platform is built, particularly the the sort of commercial commercial modern platform is built with open API framework, and, therefore, this isn't an issue for us going forward. And increasing that's gonna be the direction of travel, I think, as the landscape evolves.

25:25 You have shown $12,800,000 of ARR today and a two year strategy is designed to produce progressively stronger ARR growth. What level of ARR EBITDA margin and cash generation would you regard as successful execution of this strategy two years from now? And how would you support shareholder value materially above the current FSP price? I mean so we're not at liberty to discuss the specific numbers. There is obviously guidance out there in the market. But if I refer you back to the the two year framework that we've agreed at the board, this has also been informed by the by the feedback of, as I said, between forty and fifty different, bidder conversations and quite an enhanced level of due diligence. And that's helped us triangulate on the metrics that really matter when one's considering an external proposal, what they what what those bidders that bidder universe will focus on. And that's why you have to get the balance right between EBITDA, cash generation, and sustained quality revenue growth, not chasing any revenue. That's not interesting to these parties. So we're confident that with that feedback in mind and given where we already got proposals to today, that with continued execution, we're confident we can get those proposals to where we want them to be able to recommend a deal to shareholders should it should arise.

26:42 And final question. How do hardware states fit into platform unification? For example, will it be two states with one platform? Yeah. I mean, again, to go go back to what we said in the in the in the presentation, the existing installed medical base, which has currently has its own hardware in place, will carry on with its own hardware in place. That hardware, to to make it simple, will be pointed into the new platform. So that's those two the the commercial medical hardware states will remain as they currently are. Going forwards, of course, with a lower cost to serve, we have for net new medical customers, we have the option of bringing in the commercial hardware, which is typically more cost effective and more, user friendly in terms of self install. So that becomes just an additional upside when we're thinking about net new customer acquisition.

27:33 That's great. Thank you for answering those questions you can from investors. And, of course, the company can review all questions submitted today, and we'll publish those responses on the Investor Meet company platform. Just before redirecting investors to provide you with their feedback, which I know is particularly important to the company, KIT, could I please just ask you for a few closing comments? Yes. I mean, look. Again once again, it's been a it's been a very long and interesting half so far. But as I said, as we've repeatedly said, the feedback and the learnings from the the FSP are actually helping inform the clarity clarity of the strategy in which we're executing. They've, in fact, validated a lot of the decisions we've taken. So we remain as optimistic as we have throughout this process on our ability to continue to execute and indeed drive further value for shareholders down the line. That's great. Thank you for updating investors today.

28:21 Now please ask investors not to close this session as you'll now be automatically redirected to provide your feedback in order that the management team can better understand your views and expectations. This may take a few moments to complete, and I'm sure be greatly valued by the company. On behalf of the management team, we'd like to thank you for attending today's presentation, and good afternoon to you all.

Follow Checkit PLC into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Kit Kyte

CEO at CHECKIT PLC

Kris Shaw

CFO at CHECKIT PLC

More from Checkit PLC